Phase 1, Open Label, Dose-Escalation, Safety, Pharmacokinetic And Pharmacodynamic Study Of Single Agent PF-03758309, An Oral PAK4 Inhibitor, In Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2013
At a glance
- Drugs PF 3758309 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 09 May 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 23 Jan 2012 Actual end date changed from Jan 2012 to Dec 2011 as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual end date changed from Nov 2011 to Jan 2012 as reported by ClinicalTrials.gov.